Abstract Angiosarcoma is a rare complication of breast cancer treatment. In order to define predictors, clinical presentation, and outcome, we characterized a populationbased 50-year cohort of angiosarcomas after breast cancer. Clinical data were collected from all females with previous breast cancer who developed angiosarcomas/lymphangiosarcomas on the thoracic wall/upper extremity between 1958 and 2008 in the Southern Swedish health care region. In total, 31 angiosarcomas developed at a median age of 71 years. The patients formed two distinct groups; 14 females treated for breast cancer with radical mastectomy and radiotherapy 1949-1988 developed angiosarcomas in edematous arms (Stewart-Treves syndrome) after median 11 years, and 17 females treated by segmental resection, anti-hormonal treatment and radiotherapy 1980-2005 developed angiosarcomas in the irradiated field on the thoracic wall after median 7.3 years. The clinical presentations were heterogeneous and included hematoma-like lesions, multiple bluish-reddish nodules, and asymptomatic lumps. The overall 5-year survival was 16%. In this population-based cohort, the early angiosarcomas developed in edematous arms after radical mastectomies, whereas more recent cases occurred after a shorter time period in the irradiated fields following breast conserving surgery. We conclude that the clinical presentation of angiosarcomas has changed, parallel with altered treatment principles for breast cancer.
Introduction
Breast cancer affects 1 in 10 women in the western world. The prognosis is continuously improving with 4 out of 5 women alive 5 years after diagnosis. A major shift in the treatment of early-stage breast cancer occurred in the 1980s following studies which demonstrated that mastectomy could be replaced by segmental resection followed by postoperative radiotherapy with similar results [1] [2] [3] . Furthermore, in the early 1980s, chemotherapy and anti-hormonal therapies were introduced. Angiosarcoma is a rare and severe complication to treatment of breast cancer. The first case was reported in 1906 by Lowenstein who identified an angiosarcoma in an arm with severe chronic lymphedema [4] . In 1948, Stewart and Treves reported 6 cases of lymphangiosarcoma in edematous arms after mastectomy. Thereafter, the condition has been denoted Stewart-Treves syndrome [5] . Already in their initial report, Stewart and Treves suggested that these tumors could be mistaken for recurrent breast cancer. Following the initial observations, multiple reports have described angiosarcomas associated with long-standing and pronounced edema [6] [7] [8] [9] [10] . In 1987, Body et al. reported secondary cutaneous angiosarcomas within irradiated fields, and this study has been followed by a number of reports on radiation-induced angiosarcomas [9, [11] [12] [13] . Secondary sarcomas are rare long-term complications to radiotherapy, and angiosarcomas have been reported to account for about one-third of these tumors [6, 7, 14] . Angiosarcomas are composed of vascular spaces lined by atypical tumor cells. The 5-year survival rates are typically 10-15% [12, 15] . We used a population-based sarcoma cohort to characterize causative factors, clinical presentation, and outcome of angiosarcomas after breast cancer treatment.
Materials and methods
Angiosarcomas were identified on a population basis in the southern Swedish Health Care Region, which currently has an uptake area of 1.5 million inhabitants. The southern Swedish part of the national Swedish Cancer Registry (established in 1958) and the pathology register (established in 1960) were used to identify all females with angiosarcomas (ICD code 9120.3), lymphangiosarcomas (9170.3) and epithelioid hemangioendotheliomas (9133.3). Hemangiosarcoma, hemangioblastoma, lymphangioblastoma, malignant hemangioendothelioma, and malignant angioendothelioma were all considered synonymous with angiosarcoma [16] .
Women with breast cancer diagnosed prior to an angiosarcoma were selected. Further requisites were that the tumors should have been localized to the upper extremity or shoulder (ICD-9 code 171.2), the chest wall or the mediastinum (171.4), the abdomen (171.5), the thoracic wall (171.7), or at an unspecified location (171.9). In order not to disregard breast cancers diagnosed before the establishment of the registry, women with an angiosarcoma diagnosed before 1979 were included, independent of previous cancer status. Hereby, 69 cases were identified and clinical data could be retrieved from 67/69 cases (97%) with the missing cases being diagnosed before 1980. We excluded 38 cases because they did not meet the inclusion criteria due to other tumor sites or erroneous classifications.
Hence, 31 women with confirmed angiosarcomas after treatment for breast cancer were eligible for the study.
Ethical permission for the study was granted by the Lund University Ethics Committee. For statistical analysis the logrank test was performed using Stata 11.0 (StataCorp LP, College Station, TX, USA).
Results

Breast cancer therapy and time to angiosarcoma
The median age at breast cancer diagnosis was 61 (range 35-83) years and at sarcoma diagnosis 71 (range 43-93) years ( Table 1 ). The median time from radiation therapy to sarcoma development was 9 (range 3-25) years. Two clinical patterns were observed; angiosarcomas that developed in edematous arms/shoulder regions, i.e., Stewart-Treves syndrome, and lesions that developed in the irradiated field on the thoracic wall.
The Stewart-Treves group consisted of 14 females who had undergone mastectomy and axillary nodal dissection followed by radiotherapy between 1949 and 1988. These women had been diagnosed with breast cancer at a median age of 61 years (bilateral breast cancers had been diagnosed in 3 cases) and angiosarcoma at a median age of 72 years, i.e., 11 years (range 3-25; 95% CI 9.0-19) later ( Table 2 , Fig. 1 ). All 14 women suffered from edema in the affected arm. The doses and types of radiotherapy varied within this group. Anti-hormonal therapy was administered to 5/14 women, whereas none received chemotherapy.
Angiosarcomas in irradiated fields developed in 17 females, all of whom had undergone breast cancer treatment between 1980 and 2005 (16 cases with segmental resection, 1 case of modified radical mastectomy, in all cases followed by radiotherapy for breast cancer). In this subset, breast cancer had been diagnosed at a median age of 62 years and angiosarcoma at median 69 years of age, with a median interval of 7.3 years (range 3-15; 95% CI 5.8-8.8) ( Table 2 , Fig. 1 ). Axillary nodal dissection had been performed in all but one case, but information on arm edema was specified only in 6 cases, with edema reported in 2 cases. All of these angiosarcomas developed within the irradiated fields on the thoracic wall. Most women in this group had received 50 Gy in 2 Gy daily fractions over 5 weeks. Anti-hormonal therapy had been administered to 7/17 women and 2 had been treated with chemotherapy.
The time from breast cancer to sarcoma differed between the groups, from median 11 years in the StewartTreves group to 7.3 years in the group with angiosarcomas in irradiated fields (P = 0.01, log-rank test). Median follow-up for the patients in the Stewart-Treves group was 19 (0-65) months and for patients with angiosarcomas in irradiated fields 12 (2-88) months. All 14 women in the former group were dead, 10 of them from the angiosarcoma. In the latter cohort 6/17 patients are still alive and 7 had died from angiosarcoma (Table 1) . Median time to angiosarcoma-specific death was 15 months in the Stewart-Treves group and 4 months in the irradiated-field group. The overall 5-year survival in the total cohort was 16%.
Discussion
Angiosarcoma is a rare complication of breast cancer treatment and in our population-based, 50-year cohort, we identified 31 females with angiosarcomas of the thoracic wall, shoulder or arm following breast cancer treatment. Two distinct groups were recognized; angiosarcomas in edematous upper arms, i.e., Stewart-Treves syndrome, diagnosed before 1988, and tumors in irradiated fields on the thoracic wall, diagnosed after 1980 (Fig. 1) . The distinct change in clinical presentation occurred parallel with altered treatment principles for early-stage breast cancer. Modified radical mastectomy, axillary nodal dissection, and radiotherapy composed the treatment until the 1980s, with a substantial risk of edema. Since then less aggressive surgery, i.e., breast conservative treatment and selective dissection of axillary nodes, in combination with postoperative radiotherapy and anti-hormonal treatment or chemotherapy is considered standard treatment [1, 2] .
Before 1970-1980, radiotherapy was poorly standardized. Treatment was generally administered postoperatively and used orthovoltage techniques with doses of about 300 rad (approximately 3 Gy) per fraction and split course treatment. During the 1970s linear accelerators were introduced and radiotherapy was given with combined orthovoltage and megavoltage techniques, typically with 2.5 Gy daily doses in 2 to 3 series. In the 1980s radiotherapy was standardized with the commonest treatment being 48 Gy in 20 fractions in 2 series, with a combination of electron (to the parasternal nodes and the thoracic wall) and megavoltage photon (to axillary and supraclavicular nodes) treatment.
Angiosarcomas in irradiated fields following breastconservative surgery developed median 4 years earlier than in the Stewart-Treves group. Also symptom duration before diagnose was shorter in this group, median 4 months, than in the Stewart-Treves group, median 6 months. Intervals of 4-12 years between breast cancer and angiosarcoma have been reported also by other investigators with lower time estimates in recent studies, which likely reflect a larger contribution from radiationinduced sarcomas in recent cases [9, 12, 14, [17] [18] [19] . In our cohort, extensive or breast conservative surgery constituted the major difference between the groups since all women had been treated with radiotherapy (Table 1) . Our observation of a changing clinical presentation of angiosarcoma is supported by other investigators. A study from Western Sweden reported 6 angiosarcomas, all of which developed in edematous arms 7-14 years after treatment (including radiotherapy) for breast cancer during the time period 1960-1980 [6] . Billings et al., described 27 cutaneous angiosarcomas following conservative surgery and radiotherapy for breast cancer with a median time to angiosarcoma that was shorter than the time reported in the literature for patients with Stewart-Treves syndrome [9] .
Atypical vascular lesions have been reported in irradiated field after treatment for breast cancer, but whether these lesions represent precursors of angiosarcoma is Fig. 1 Time line demonstrating the distribution of breast cancers (circles) and angiosarcomas (squares) over time. Tumors that developed in the same individual are joined. Green symbols represent cases linked to edematous arms (Stewart-Treves syndrome), whereas red symbols define angiosarcomas that have developed within irradiated fields on the thoracic wall. The increasingly steeper slopes reflect the shorter time to angiosarcoma in more recent cases controversial and many angiosarcomas also contain areas with atypical vascular cellularity [12, 13, 20] . Discoloration of the skin followed by hematoma-like lesions and sometimes subsequent appearance of multiple bluish-reddish nodules was in our series reported by 13 women, whereas the remaining 18 females presented with subcutaneous lumps without cutaneous precursors (although they sometimes were ulcerated once the patient sought medical attention). Angiosarcoma carried a poor prognosis with a 5-year survival of 16% in our study, compared to 10-15% reported in the literature [12, 15] . The time to angiosarcoma-specific death seemed to be shorter for the cases presenting with angiosarcoma within the irradiated field. If this is due to a more aggressive tumor form is unclear.
In summary, this population-based study demonstrates that angiosarcoma remains a rare complication of breast cancer treatment, and reveals distinct differences in presentation, latency time, and tumor location linked to altered treatment principles for breast cancer. With an increasing incidence of breast cancer (from 86/100 000 in the southern Swedish Health Care Region in 1970 to currently 167/100 000), early diagnosis and improved treatment, an increasing number of patients become long-term survivors. Thus, a larger group is at risk of this late treatment complication. Our series specifically addressed angiosarcomas, which has been estimated to represent one-third of radiation-induced sarcomas, suggesting that additional sarcomas of other histology appear in the cohort studied [6, 7, 14] . Several issues remain to be clarified, e.g., whether individual risk factors for angiosarcoma development can be identified, whether the biological profiles differ depending on causative factor, and how treatment should be optimized in this rare and severe complication to breast cancer treatment.
